The goal of the EU F-gas Legislation is to reduce the EU’s F-gas emissions by 2/3 by 2030, compared to levels in 2014. While GAAPP supports net carbon neutral solutions, the impact of the legislation to patients with chronic respiratory illnesses must be considered during the proposed phase down of these devices. We know that inhaled therapy is a critical medical intervention in managing respiratory patients. Currently, pressurized metered-dose inhalers (pMDI) devices contain a molecule that has a global warming impact. Hydrofluorocarbons (HFCs) used for medical purposes are currently exempt, however this exemption may be removed. Presently, 70% of inhalers are produced in Europe, which can create a supply chain issue globally. GAAPP wants to ensure patient access globally is not hindered because of this initiative.

GAAPP and other stakeholders have engaged with the EU Commission to highlight impacts of the EU F-gas Legislation for patient care and educate on ongoing work to innovate next generation propellants. GAAPP has submitted comment to reflect the concerns, and a recommendation for a slower phase down approach and the increased patient involvement in the discussions.

Read GAAPP’s Full Comments Here (link to PDF).